Zum Inhalt

Shigella flexneri 1c bacteremia in a child: a case report

  • Open Access
  • 14.02.2026
  • Case Report
Erschienen in:

Abstract

Background

Shigellosis is a significant public health issue in developing countries, particularly affecting young children under the age of five. While it primarily causes gastrointestinal infections, there are rare complications, such as bacteremia, that mainly occur in young children. We present a case of dysentery caused by Shigella flexneri serotype 1c, followed by bacteremia.

Case presentation

A 13-month-old Afghan child presented with fever, dysentery, distended abdomen, mild tenderness, and dehydration. He did not respond to empirical treatment with ceftriaxone. However, he was successfully treated with a combination of gentamicin and ciprofloxacin. This is the first report of a patient in Iran who was positive for S. flexneri serotype 1c and harbored the ipaB, ipaC, ipaD, ipaH, ipgD, virA, and sen virulence factors.

Conclusions

This case alerts clinicians to consider the possibility of Shigella bacteremia in young children. Early and accurate diagnosis can improve management and prognosis to reduce the risk of fatality outcomes. Additionally, it emphasizes the need to characterize the role of Shigella spp. virulence genes in causing bacteremia.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Background

Although the prevalence of Shigellosis has recently decreased, it continues to be an essential public health problem in developing countries [1]. This bacterium is a highly transmissible enteric pathogen associated with the third leading cause of diarrheal deaths among children under five [2]. Four species are responsible for Shigellosis, among which S. flexneri and S. sonnei are the most common causes in developing countries, including Iran [35]. Shigella spp. is more often the cause of moderate-to-severe diarrhea (MSD) and dysentery among children aged < 5 years living in developing or under-developed countries [6]. However, extraintestinal complications, including bacteremia, are a relatively rare event, occurring primarily in neonates, malnourished children, and the immunosuppressed [7]. In this article, we present a case of a 13-month-old infant who developed episodes of dysentery caused by S. flexneri serotype 1c, which was followed by bacteremia.

Case presentation

A 13-month-old Afghan boy was admitted to Hakim Hospital in Tehran, Iran, on 17 November 2024, after experiencing multiple episodes of dysentery and a 38 °C fever for the past five days. The child belonged to a low socio-economic status and lived in the suburbs of Tehran. Recently, all of his family members had experienced dysentery.
On physical examination, the infant weighed 10 kg. He was ill-looking, with a distended abdomen, mild tenderness in the periumbilical region, and 6% dehydration. Prior to prescribing antibiotics, blood and stool cultures, along with other relevant investigations, were conducted. Stool cultures were done three times. Three sets of blood culture, each containing 3 mL of blood, were transferred into each blood culture bottle under sterile conditions, and cultures were processed using a manual blood culture system. The blood analysis from the laboratory showed the following results: hemoglobin level was 10.3 g/dl, and the total leukocyte count was 7300/µl (Reference Range: 4500–11000/µl). This included 47% neutrophils, 38% lymphocytes, 12% monocytes, 3% eosinophils, and 0% basophils. The platelet count was 151,000 /µl. Additionally, the serum sodium concentration was 132 mEq/L, the erythrocyte sedimentation rate (ESR) was 52 mm/hr, the BUN level was 7 mg/dL, the creatinine level was 0.3 mg/dL, and the C-reactive protein was measured at 385 mg/L. The stool results indicated many WBCs, many/hpf; RBC, 8–10/hpf; and no parasite found. The child was immediately rehydrated with dextrose saline with potassium chloride supplementation. Intravenous ceftriaxone (500 mg) was administered every 12 h.
To help reduce fever, intravenous acetaminophen (Apotel) 100 mg was prescribed, with a maximum of every six hours. The ultrasound revealed no signs of invagination (intussusception), in which one segment of intestine telescopes inside another in the patient.
However, the patient continued to experience fever and dysentery and did not respond to initial empirical treatment. As a result, ciprofloxacin (100 mg) was replaced with ceftriaxone (500 mg), administered every 12 h. The cultures and susceptibility reports were completed five days after the patient was admitted to the hospital. Based on these results, gentamicin (25 mg) was added to the treatment regimen every 8 h. After 48 h, the frequency of diarrhea gradually decreased. The treatment was continued for 10 days, and the patient was discharged in stable condition after a 14-day hospital stay.
As mentioned previously, stool and blood samples were cultured for bacterial identification. The cultures from both blood and stool tested positive for S. flexneri in the first two sets. However, the third set of tests for both blood and stool cultures was negative, after which appropriate antibiotics were prescribed. According to CLSI guidelines, the isolate was sensitive to ceftazidime (CAZ; 30 µg), meropenem (MR; 10 µg), doripenem (DOR; 10 µg), ertapenem (ETP; 10 µg), doxycycline (DXT; 30 µg), chloramphenicol (C; 30 µg ), ciprofloxacin (CIP; 5 µg), levofloxacin (LEV; 5 µg), ofloxacin (OFX; 5 µg), gatifloxacin (GAT; 5 µg), minocycline (MN; 30 µg), tigecycline (TGC; 15 µg), azithromycin (ATH; 15 µg), gentamicin (GM; 10 µg), tetracycline (T; 30 µg), susceptible dose dependent to cefepime (FEP; 30 µg), intermediate to imipenem (IPM; 10 µg), amikacin (AK; 30 µg), nalidixic acid (NA; 30 µg) and resistant to ampicillin (AM; 10 µg), cefotaxime (CTX; 30 µg), ceftriaxone (CRO; 30 µg), cefixime (CFM; 5 µg) and cotrimoxazole (SXT; Trimethoprim 1.25 µg, Sulfamethoxazole 23.75 µg) by the Kirby-Bauer method using antibacterial disks (Mast, UK) [r8]. The minimum inhibitory concentration (MIC) of azithromycin, determined by the agar dilution method, was 2 µg/ml, indicating susceptibility to the antibiotic. Based on the Multiplex PCR and PCR methods described previously, S. flexneri belonged to serotype 1c and also harbored the ipaB, ipaC, ipaD, ipaH, ipgD, virA, and sen virulence genes [3, 9] (Fig. 1).
Fig. 1
A: Multiplex PCR product of S. flexneri serotyping. Lane 1, Molecular size markers (100-bp DNA ladder; SMOBIO, South Korea); lane 2, S. flexneri serotype 1c; lane 3, Negative control. B: PCR products of S. flexneri virulence factors genes. Lane 1, ipaB; lane 2, ipaC; lane 3, ipaD, lane 4, Molecular size markers (100‐bp DNA ladder; SMOBIO, South Korea), lanes 5, ipaH; lane 6, virA; lane 7, ipgD; lane 8, sen; lane 9, Negative control
Bild vergrößern

Discussion and conclusions

Shigella infections primarily affect the gastrointestinal system. In contrast, extraintestinal infections, such as those affecting the bloodstream, are rare and mainly occur in children and immunocompromised adults [10, 11]. Specifically, bacteremia is seen in only 0.4% to 7.3% of cases in heterogeneous populations, including children to adults and in patients with cystic fibrosis, and this is mainly linked to infections caused by S. flexneri and S. dysenteriae [1114]. Shigella-induced bacteremia should be regarded with seriousness because it can significantly increase mortality rates [12, 15, 16]. In this case, the infection was caused by S. flexneri, consistent with previous case reports [1719]. However, some studies indicate that other Shigella species can also cause bacteremia [11, 2022].
Multiplex PCR results indicated that S. flexneri serotype 1c, which was detected in the patient, has increased in developing countries over the past decade [23]. The result was inconsistent with previous results done in the adult population, which documented serotypes 1b, 2, 2a, 3, and 4a as the responsible serotypes [2426]. Notably, these earlier serotypes were isolated from adult populations.
The reasons behind the development of bacteremia after a gastrointestinal infection are not fully understood. However, several factors may contribute, including the virulence of the pathogen, the initial bacterial burden, damaged mucosal barriers, and weakened host immunity [7].
Shigella pathogenesis involves several virulence factors encoded on chromosomal pathogenicity islands and a virulence plasmid. The ipa and ipg genes are crucial in invading epithelial cells and initiating Shigella infection [27]. The invasion plasmid antigen H (ipaH), a key target for the molecular identification of Shigella species, is essential in invading and modulating host inflammatory responses during bacterial infections [28]. We also identified the ipaB, ipaC, and ipaD genes, which encode proteins playing a crucial role in colonic epithelial cell invasion and intracellular survival, as well as translocating various effector proteins [9]. The invasion plasmid gene D (ipgD), which enhances immune evasion and facilitates cell-to-cell spread by disrupting communication between host cells, was identified in our isolate [27, 29]. The virA is another virulence factor in our isolate and is involved in Shigella’s uptake, invasion, and cell-to-cell transmission within the human host [30]. Our patient continued to have watery diarrhea during the hospitalization, which is hypothesized to be associated with the presence of the sen gene [27]. The World Health Organization (WHO) claims that all cases of bloody diarrhea should be treated with antibiotics. Effective antibiotic therapy lowers the risk of serious complications and death, shortens symptom duration, and decreases the shedding of organisms in stools [16, 31]. In our case, S. flexneri was resistant to ampicillin, cefotaxime, ceftriaxone, cefixime, and cotrimoxazole. There are different mechanisms by which Shigella spp. can develop resistance to the therapeutic antibiotics, including production of enzymes (such as β-lactamases), cellular impermeability, alternate metabolic pathways, extrusion of drugs by efflux pumps overexpression, and drug treatment mutation [32, 33]. As a result, the initial empirical treatment with ceftriaxone was unsuccessful. However, a subsequent change in the treatment regimen to gentamicin and ciprofloxacin, to which the isolate was susceptible, resulted in a successful clinical outcome and complete resolution of the infection. Jain et al., from Delhi, reported a case of S. flexneri septicemia in an infant that was also resistant to ceftriaxone, resulting in the patient’s death [19]. In contrast, some studies indicated that ceftriaxone remains an appropriate option for treating S. flexneri bloodstream infection [7, 17, 18].
Along with antibiotic resistance, other risk factors, rather than antibiotic resistance, should also be considered in the development of Shigella bacteremia and its associated mortality. Few studies have addressed these risks. However, host factors such as age, malnutrition, non-breastfeeding, and immunocompromised status have been linked to death from Shigella bacteremia [34, 35].
In conclusion, although S. flexneri bacteremia is rare, it occurs mainly in children under five years of age. Therefore, blood and stool cultures should be taken for better management and prognosis in bloody gastroenteritis with fever in children. An early and accurate diagnosis is crucial because appropriate antibiotics and supportive care can be lifesaving for such patients. This study was the first report of Shigella flexneri serotype 1c isolated from blood in Iran, which possessed all investigated virulence factors. However, it remains uncertain whether this serotype possesses increased virulence. This rare case highlights the need for clinicians and microbiologists to characterize the role of these genes and other related virulence factors of Shigella spp. for successfully spreading this pathogen into blood circulation.

Acknowledgements

We want to express our sincere gratitude to the laboratory and infection section staff for their exceptional dedication and contributions.

Declarations

Not applicable.
Not applicable.

Competing interests

The authors declare no competing interests.

Clinical trial

Not applicable.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Download
Titel
Shigella flexneri 1c bacteremia in a child: a case report
Verfasst von
Mehrzad Sadredinamin
Zohreh Ghalavand
Maryam Rostamyan
Raana Kazemzadeh Anari
Seyyed Mohammadreza Hosseini Imeni
Bahram Nikmanesh
Publikationsdatum
14.02.2026
Verlag
BioMed Central
Erschienen in
Gut Pathogens / Ausgabe 1/2026
Elektronische ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-026-00804-w
1.
Zurück zum Zitat Tsai C-S, Wang J-L, Liao Y-S, Fukushige M, Chiou C-S, Ko W-C. Shigellosis in taiwan: an old enteric pathogen with changing epidemiology and increasing antimicrobial resistance. J Microbiol Immunol Infect. 2024;57(3):346–53.CrossRefPubMed
2.
Zurück zum Zitat Kotloff KL. Shigella infection in children and adults: a formidable foe. Lancet Global Health. 2017;5(12):e1166–7.CrossRefPubMed
3.
Zurück zum Zitat Sadredinamin M, Shabani M, Karimi A, Sohrabi M-R, Karimi-Yazdi M, Ghalavand Z, et al. Virulence genes expression profiling of different Shigella flexneri serotypes in response to sub-inhibitory concentrations of Azithromycin and Ciprofloxacin. Gut Pathogens. 2022;14(1):10.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Moosavian M, Ghaderiyan GH, Shahin M, Navidifar T. First investigation of the presence of SPATE genes in Shigella species isolated from children with diarrhea infection in Ahvaz, Southwest Iran. Infect Drug Resist. 2019 ;12:795–804. https://doi.org/10.2147/IDR.S194740
5.
Zurück zum Zitat Ewing WH. Shigella nomenclature. J Bacteriol. 1949;57(6):633–8.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Libby TE, Delawalla ML, Al-Shimari F, MacLennan CA, Vannice KS, Pavlinac PB. Consequences of Shigella infection in young children: a systematic review. Int J Infect Dis. 2023;129:78–95.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Davies N, Karstaedt A. Shigella bacteraemia over a decade in Soweto, South Africa. Trans R Soc Trop Med Hyg. 2008;102(12):1269–73.CrossRefPubMed
8.
Zurück zum Zitat CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 34th Edition. Clinical laboratory Standards institute; 2024.
9.
Zurück zum Zitat Karimi-Yazdi M, Ghalavand Z, Shabani M, Houri H, Sadredinamin M, Taheri M et al. High rates of antimicrobial resistance and virulence gene distribution among Shigella spp. isolated from pediatric patients in Tehran, Iran. Infection and drug resistance. 2020:485 – 92.
10.
Zurück zum Zitat Muthuirulandi Sethuvel DP, Devanga Ragupathi NK, Ninan MM, Michael JS, Anandan S, Veeraraghavan B. Differential gene expression profile of Shigella dysenteriae causing bacteremia in an immunocompromised individual. Future Sci OA. 2020;6(4):FSO456.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Nayyar C, Thakur P, Tak V, Singh A. Shigella sonnei sepsis in an infant: A case report. J Clin Diagn Res. 2017;11(5):Dd01–2.PubMedPubMedCentral
12.
Zurück zum Zitat Kamble R. Bacteraemia due to Shigella flexneri in an adult. Int J Curr Microbiol App Sci. 2015;4(4):870–73.
13.
Zurück zum Zitat Carretero-Vicario O, Taravillo I, Corbella L, Catalan M, Garfia C, Martinez MT, et al. Shigella sonnei bacteraemia in a cystic fibrosis patient: case report and literature review. Access Microbiol. 2020;2(2):e000102.CrossRef
14.
Zurück zum Zitat Khan WA, Griffiths JK, Bennish ML. Gastrointestinal and extra-intestinal manifestations of childhood shigellosis in a region where all four species of Shigella are endemic. PLoS ONE. 2013;8(5):e64097.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Al Soub H, Al Maslamani M, Al Khuwaiter J, El Deeb Y, El-Shafie SS. Shigella flexneri perinephric abscess and bacteremia. Ann Saudi Med. 2005;25(5):419–21.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Samandari T, Okafor CN. Shigellosis. StatPearls. Treasure Island (FL)2025.
17.
Zurück zum Zitat Gupta R, Gupta V, Bhat D, Goyal R, Chaudhary J, Gupta M. Shigella flexneri sepsis in a Well-nourished immunocompetent child: A rare case report. J Gastrointest Infections. 2021;11:44.
18.
Zurück zum Zitat Yen J-B, Chang K-W, Wu T-L, Kuo A-J, Su L-H. Shigella flexneri sepsis in an infant. World. 2003;6:8.
19.
Zurück zum Zitat Jain S, Sharma M, Gupta R, Shree N, Kumar M. Multidrug resistant Shigella flexneri: a rare case of septicemia in an infant. J Clin Diagn Research: JCDR. 2014;8(6):DD03.
20.
Zurück zum Zitat Shogbesan O, Rettew A, Shaikh B, Abdulkareem A, Donato A. Shigella sonnei bacteremia presenting with profound hepatic dysfunction. Case Rep Gastrointest Med. 2017;2017(1):7293281.PubMedPubMedCentral
21.
Zurück zum Zitat Huynh A, McGrath C, Johnson D, Burrell LM. Shigella sonnei bacteraemia occurring in a young man with shigellosis. Case Rep. 2015;2015:bcr2014208875.
22.
Zurück zum Zitat Markham KB, Backes C, Samuels P. Bacteremia and intrauterine infection with Shigella sonnei in a pregnant woman with AIDS. Arch Gynecol Obstet. 2012;286:799–801.CrossRefPubMed
23.
Zurück zum Zitat Parajuli P, Minh BQ, Verma NK. Newly emerged serotype 1c of Shigella flexneri: multiple origins and changing drug resistance landscape. Genes. 2020;11(9):1042.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Tobin-D’Angelo M, Oosmanally N, Wilson SN, Anderson EJ, Segler S, Poventud L. Shigella bacteremia, Georgia, USA, 2002–2012. Emerg Infect Dis. 2020;26(1):122.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Ninan MM, George TK, Balaji V, Ramya I. Extended spectrum β-lactamase producing Shigella flexneri serotype-2 causing bacteremia in a patient with uncontrolled diabetes mellitus. Indian J Pathol Microbiol. 2016;59(3):420–1.CrossRefPubMed
26.
Zurück zum Zitat Grondin C, Imbert P, Ficko C, Mérens A, Dutasta F, Bigaillon C, et al. Shigella flexneri bacteremia in two Immune-Competent adult travelers. J Travel Med. 2012;19(4):258–60.CrossRefPubMed
27.
Zurück zum Zitat Mattock E, Blocker AJ. How do the virulence factors of Shigella work together to cause disease?>. Frontiers in cellular and infection microbiology. 2017;7:249163. https://doi.org/10.3389/fcimb.2017.00064
28.
Zurück zum Zitat Dranenko NO, Tutukina MN, Gelfand MS, Kondrashov FA, Bochkareva OO. Chromosome-encoded IpaH ubiquitin ligases indicate non-human enteroinvasive Escherichia. Sci Rep. 2022;12(1):6868.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Köseoğlu VK, Jones MK, Agaisse H. The type 3 secretion effector IpgD promotes S. flexneri dissemination. PLoS Pathog. 2022;18(2):e1010324.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Germane KL, Ohi R, Goldberg MB, Spiller BW. Structural and functional studies indicate that Shigella VirA is not a protease and does not directly destabilize microtubules. Biochemistry. 2008;47(39):10241–3.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Organization WH. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005.
32.
Zurück zum Zitat Ranjbar R, Farahani A, Shigella. Antibiotic-Resistance mechanisms and new horizons for treatment. Infect Drug Resist. 2019;12:3137–67.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Das B, Patra S. Antimicrobials: meeting the challenges of antibiotic resistance through nanotechnology. Nanostructures for antimicrobial therapy: Elsevier; 2017. pp. 1–22.
34.
Zurück zum Zitat Gutierrez A, Gautam S. Antibiotic-Resistant Shigella sonnei bacteremia in an immunocompetent postgastric bypass patient without typical risk factors. Case Rep Infect Dis. 2025;2025(1):9910105.PubMedPubMedCentral
35.
Zurück zum Zitat Struelens MJ, Patte D, Kabir I, Salam A, Nath SK, Butler T. Shigella septicemia: prevalence, presentation, risk factors, and outcome. J Infect Dis. 1985;152(4):784–90.CrossRefPubMed

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Fokale Salvage-Therapie bei lokalem Prostatakrebsrezidiv langfristig wirksam

Bei einem nach Radiotherapie lokal rezidivierten Prostatakarzinom sind fokale Salvage-Therapien mit einer guten Prognose verbunden: Das krebsspezifische Zehn-Jahres-Überleben ist einem retrospektiven Vergleich zufolge ebenso hoch wie nach Salvage-Prostatektomie.

Relacorilant verlängert Überleben bei platinresistentem Ovarialkarzinom

Durch Hinzunahme des Glukokortikoid-Rezeptor-Antagonisten Relacorilant zu nab-Paclitaxel wird bei Frauen mit platinresistentem Ovarialkarzinom nicht nur das progressionsfreie, sondern auch das Gesamtüberleben verlängert. Laut finaler Analyse der ROSELLA-Studie gewinnen sie vier Monate an Lebenszeit.

ICI-induzierte Dermatitis: Upadacitinib als vielversprechende Therapieoption

Immunvermittelte Hautreaktionen gehören zu den häufigsten Nebenwirkungen von Immun‑Checkpoint‑Inhibitoren. Eine offene Phase‑2‑Studie untersuchte den JAK‑1‑Inhibitor Upadacitinib bei schwerer ICI‑assoziierter Dermatitis. Die Hautsymptome gingen rasch zurück, schwerwiegende therapieassoziierte Nebenwirkungen wurden nicht beobachtet.

Extrapulmonale Befunde beim Lungenkrebs-Screening – Krebsverdacht gerechtfertigt?

Der Umgang mit Zufallsentdeckungen ist ein vieldiskutiertes Thema im Zusammenhang mit dem Low-Dose-CT-Screening auf Lungenkrebs. Eine Studie hat sich nun speziell mit inzidentellen Befunden befasst, die auf ein extrapulmonales Malignom verdächtig sind.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Bildnachweise
Die Leitlinien für Ärztinnen und Ärzte, Eine Person kratzt sich am Rücken über der Schulter/© ryanking999 / stock.adobe.com (Symbolbild mit Fotomodell), Mann erhält einen CT-Scan /© Mark Kostich / stock.adobe.com (Symbolbild mit Fotomodell)